In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax ...

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

As CLL progresses and treatment is required, many treatment options are available. Treatments may be individualized and based ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Chronic lymphocytic leukemia-- or CLL-- is a type of cancer ... but because of the change-- called a mutation-- faulty white blood cells that don't work like they should are made instead.

The advent of targeted therapies against FLT3 and IDH1/2 mutations underscores the clinical impact of molecular profiling. Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL ...

Favorable mutations include PML::RARA and RUNX1::RUNX1T1 ... and Lymphomas Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) CLL/SLL prognosis is closely linked to IGVH ...